Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
QL1706 + eribulin + anlotinib
- Development stage
- Unknown
- Lead developer
- Qilu Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
QL1706 + eribulin + anlotinib is a multimodal combination therapy regimen being investigated for the treatment of advanced or metastatic soft tissue sarcoma. The regimen consists of **QL1706 (epalrotokewali)**, a bifunctional antibody that simultaneously targets programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4); **eribulin**, a non-taxane microtubule dynamics inhibitor; and **anlotinib**, a multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1/2/3, FGFR1-4, PDGFR alpha/beta, and c-Kit. In clinical study contexts, such as the RITEA trial led by Fudan University, this combination is often administered alongside hypofractionated radiotherapy. The strategy aims to leverage the synergistic effects of dual checkpoint blockade, cytotoxic chemotherapy, and anti-angiogenic targeted therapy to improve outcomes in patients who have failed standard prior treatments.
- Other names
- Epalrotokewali + eribulin + anlotinibRITEA regimenQL1706 + Eribulin + Anlotinib + Radiotherapy
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)FGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)FGFR4 (Fibroblast growth factor receptor 4)PDCD1 (Programmed cell death protein 1 receptor)PDGFRA (Platelet-derived growth factor receptor alpha)PDGFRB (Platelet-derived growth factor receptor beta)TUBB (Tubulin (alpha and beta subunits))VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)
Beyond the preview
Go deeper on QL1706 + eribulin + anlotinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on QL1706 + eribulin + anlotinib.